Unstable angina
Drug research and approvals for unstable angina: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 33 studies of unstable angina are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 33
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 3
- Analysis of Life-threatening ARrhythMias After Acute Coronary SyndromeNCT07824050 · Not reported · Catharina Ziekenhuis Eindhoven · starts Jul 14, 2026
- Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary SyndromeNCT07824323 · Phase 4 · Taipei Medical University Hospital · starts Aug 26, 2026
- Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary SyndromeNCT07684742 · Phase 4 · Gyeongsang National University Hospital · starts Jul 1, 2026
- Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in WomenNCT07593157 · Not applicable · Hospital de Clínicas Dr. Manuel Quintela · starts May 15, 2026
- Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery DiseaseNCT07444957 · Not reported · Fundación Interhospitalaria para la Investigación Cardiovascular FIC · starts Jan 5, 2026
- Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery…NCT07368933 · Not applicable · Advanced NanoTherapies · starts Dec 15, 2025
- Clinical Characteristics, Frailty, and Prognostic Predictors in Patients Aged 75 and Older With Acute Coronary SyndromeNCT07366684 · Not reported · Clinical Center Niš · starts May 13, 2026
- POLish Registry of CArdioneuroablation and CArdioneuromodulationNCT07196397 · Not reported · SABAMED Medical Center Ltd. · starts Nov 21, 2024
- FAPO-2: Cardiac Patient Monitoring Tool for Clinical Observation and Arrhythmia DetectionNCT07174206 · Not applicable · University of Sao Paulo · starts Feb 7, 2025
Approved 6
- AbciximabIntegrin alpha-IIb/beta-3 inhibitor
- BivalirudinThrombin inhibitor
- ClopidogrelPurinergic receptor P2Y12 antagonist
- FondaparinuxAntithrombin-III activator
- PrasugrelPurinergic receptor P2Y12 antagonist
- EptifibatideIntegrin alpha-IIb/beta-3 inhibitor
Phase 3 6
- ProgesteroneProgesterone receptor agonist
- Enoxaparin sodiumAntithrombin-III activator
- Estrogens, conjugatedEstrogen receptor agonist
- RivaroxabanCoagulation factor X inhibitor
- Insulin humanInsulin receptor agonist
- Dextrose
Phase 2 2
- ArgatrobanThrombin inhibitor
- HeparinAntithrombin-III activator
Phase 1 or earlier 1
How its trials ended
242 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 56 whose ending is known, 55% met their primary endpoint, 11% missed it and 34% stopped early.
- Completed, result not reported9941%
- Status unknown5924%
- Met its primary endpoint3113%
- Ongoing2812%
- Stopped: other or unclear104%
- Stopped: enrollment or feasibility73%
- Missed its primary endpoint62%
- Stopped: sponsor or business decision1<1%
- Stopped: funding1<1%
| May 15, 2018 | Prasugrel Viatris (previously Prasugrel Mylan)Prasugrel · generic | Viatris Limited | EMA ↗ |
| Jan 11, 2016 | Eptifibatide AccordEptifibatide · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Feb 24, 2009 | EfientPrasugrel | Substipharm | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA